Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JMKX003002
- Development stage
- Phase 2
- Lead developer
- Jemincare
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JMKX003002 is a novel small molecule drug developed by Jemincare for the treatment of hyperphosphatemia, particularly in patients with end-stage renal disease (ESRD) undergoing hemodialysis. It is currently being evaluated in phase II clinical trials to assess its efficacy and safety as an oral therapy for reducing elevated phosphate levels. The precise mechanism of action has not been publicly disclosed but it is positioned as a new molecular entity with the potential for long-lasting phosphate reduction and improved patient compliance compared to existing therapies[2][3][5]. The drug is not designated as an orphan drug.
- Other names
- JMKX 003002JMKX003002JMKX-003002
Beyond the preview
Go deeper on JMKX003002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JMKX003002.